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Abstract 
A multi-residue quantitative screening method covering 41 antibiotics from 7 different 
families, by ultra-high-performance-liquid-chromatography tandem Mass Spectrometry 
(UHPLC-MS/MS), is described. Sulfonamides, trimethoprim, tetracyclines, macrolides, 
quinolones, penicillins and chloramphenicol are simultaneously detected after a simple 
sample preparation of bovine muscle optimized to achieve the best recovery for all 
compounds. A simple sample treatment was developed consisting in an extraction with 
a mixture of acetonitrile and ethylenediaminetetraacetic acid (EDTA), followed by a 
defatting step with n-hexane. The methodology was validated, in accordance with 
Decision 2002/657/EC by evaluating the required parameters: decision limit (CCα), 
detection capability (CCβ), specificity, repeatability and reproducibility. Precision in 
terms of relative standard deviation was under 20% for all compounds and the 
recoveries between 91% and 119%. CCα and CCβ were determined according the 
maximum residue limit (MRL) or the minimum required performance limit (MRPL), 
when required.  
 
Keywords: Antibiotics, multi-class, multi-detection, UHPLC-MS/MS, muscle, 
validation.   
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1. Introduction 
In food producing animals, antibiotics are widely used and administrated as feed 
additives and in drinking water to treat and prevent diseases but also to illegally 
stimulate animal growth (Wassenaar, 2005; Laxminarayan et al., 2013).  
The continuous use of these drugs carries the risk of their presence in edible tissues 
which, for consumers, can be responsible for toxic effects and allergic reactions in 
hypersensitive individuals (Le Bizec, Pinel & Antignac, 2009). It can also result in the 
development of resistant strains of bacteria that might compromise the efficiency of 
antibiotics used for treatment of animals (Laxminarayan et al., 2013). When that occurs 
it became difficult to treat serious diseases, increasing the negative effects in animal 
welfare and consequently severe consequences for productivity and economy. 
Furthermore, the potential spread of resistant strains of bacteria from animals to humans 
can have the same effect when using antibiotics as human medicines (Doyle & 
Erickson, 2006). These concerns make the analysis of antibiotic residues in food 
producing animals an important field in food safety. To control abusive situations, and 
because food safety is a key police priority for the European Commission (Commission 
of the European Communities, 2000); several official documents were settled down to 
regulate the control of veterinary drugs in products of animal origin. The Council 
Directive 96/23/EC (European Commission, 1996) determines the measures to monitor 
certain substances and residues of veterinary medicines in living animals and in animal 
products. This directive foresees laboratorial control. For permitted veterinary drugs, 
tolerance levels were established as maximum residue limits (MRLs) in foodstuff of 
animal origin and listed in the EU Commission Regulation 37/2010 (European 
Commission, 2009 & European Commission, 2010). For non-authorized substances 
there are no tolerance levels but, for some compounds, to harmonize the analytical 
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performance of the methods, a minimum required performance limit (MRPL) had been 
set (European Commission, 2002; SANCO, 2007). The MRPL level is not a 
concentration obtained from toxicological data, but is only related with analytical 
performance. The European Decision 2002/657/EC (European Commission, 2002) 
describes the requirements for the performance and validation of the analytical methods 
employed in the official residues control. To fulfill such requirements it is important to 
have sensitive and specific analytical methodologies capable of monitoring the use or 
potential abuse of these drugs in the field of animal husbandry, ensuring that MRL 
levels are respected. The concern about having efficient screening methods is increasing 
and also about the improvement of cost-effectiveness of analytical procedures (Reig & 
Toldrá, 2008; Kaufmann, 2009; Martos et al., 2010). Typically the methods used in 
laboratory are multi-detection of related compounds, usually from the same family of 
antibiotics. That means that a single sample, to be analyzed for different groups of 
antibiotics, became part of a time consuming process that can last weeks.  The delayed 
final result is associated with high cost and turns to be questionable in terms of 
usefulness of the result. This efficiency can be gathered in multi-class and multi-
detection methods based on liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) being the tool of choice, providing the required degree of 
confidence for veterinary residues analysis in biological samples (Le Bizec, Pinel & 
Antignac, 2009; Kaufmann, 2009). Nowadays, the use of ultra-high performance liquid 
chromatography (UHPLC) provides numerous advantages in terms of resolution, 
sensitivity and also in minimizing time of analysis which is an important feature when 
running numerous samples in routine laboratories (De Brabander et al., 2009; Geis-
Asteggiante et al., 2012, Lehotay et al., 2012 and Malik, Blasco, & Picó, 2010). Despite 
that, the simultaneous determination of antibiotics from different pharmacologic 
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families in complex biological matrices, such as bovine muscle, has several constrains 
mainly related with the differences in physicochemical properties of the compounds (De 
Brabander et al., 2009; Kinsella, O’Mahony, Cantwell, Furey & Danaher, 2009).  
In the literature, only few methods, combining multi-detection and multi-class in a 
quantitative screening method for bovine muscle, are available. Martos et al. (2010) 
describes a LC-MS/MS method for the screening of 39 compounds from 7 families of 
antibiotics, although not validated. Granelli, Elgerud, Lundström, Ohlsson & Sjöberg 
(2009) presented an LC-MS/MS method for the determination of 19 compounds, from 5 
classes. A group of the US Department of Agriculture (Geis-Asteggiante, et al., 2012 
and Lehotay et al., 2012) described a qualitative screening method for the determination 
of more than 100 compounds in bovine muscle and/or in kidney, by UHPLC-MS/MS, 
including not only antibiotics, but several other drugs, such as anthelmintics, 
thyreostatics, beta-agonists, hormones, NSAIDS and tranquilizers. Although proved to 
be efficient for screening purposes, the validation presented is not based on European 
Commission requirements (European Commission, 2002). Recently, multi-detection 
methods for the analysis of veterinary drugs using liquid chromatography coupled with 
time-of-flight mass spectrometry (LC-ToF-MS) have been published (Peters, Bolck, 
Rutgers, Stolker & Nielen, 2009) and UHPLC-ToF-MS (Kaufmann, Butcher, Maden & 
Widmer, 2008). One of the main advantages is the possibility of analyzing an unlimited 
number of analytes in a single run, since the detection by ToF-MS is not limited by 
dwell time (Stolker, Zuidema & Nielen, 2007). Nevertheless, although it can be applied 
for screening and quantification purposes it cannot be used as confirmatory methods 
due to the requirements of legislation (European Commission, 2002) and always obliges 
the confirmation of positive findings using a MS/MS detector. 
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The present paper describes the development and validation of a simple and effective 
quantitative screening method by UHPLC-MS/MS for the simultaneous detection of 41 
antibiotic compounds from sulfonamides, tetracyclines, penicillins, macrolides, 
quinolones, trimethoprim and chloramphenicol in bovine muscle. Validation procedure 
followed the requirements from the European Commission Decision 2002/657/EC 
(European Commission, 2002) in order to apply the method in routine analysis. 
 
2. Material and Methods 
2.1. Reagents, Solvents and Standard Solutions 
All reagents and solvents used were of analytical grade with the exception of chemicals 
used for the mobile phase, which were of high-performance liquid chromatography 
grade. Methanol, acetonitrile and formic acid were supplied by Merck (Darmstadt, 
Germany). Ethylenediaminetetraacetic acid (EDTA) was purchased from Sigma-Aldrich 
(Madrid, Spain). All standards of sulfonamides, tetracyclines, penicillins, macrolides, 
quinolones, trimethoprim and chloramphenicol were supplied by Sigma-Aldrich 
(Madrid, Spain). The individual standards are listed in Table 1. Six internal standards 
were used: demethyltetracycline for tetracyclines, penicillin V for penicillins, 
lomefloxacin for quinolones, roxithromycin for macrolides, sulfameter for sulfonamides 
and for trimethoprim and chloramphenicol- d5 for chloramphenicol. All the internal 
standards were provided by Sigma-Aldrich. For all substances, stock solutions of 1mg 
mL-1 were prepared by weighing the appropriate amount of standard, diluted in 
methanol, and storing at -20ºC. Suitable dilutions were also prepared to have convenient 
spiking solutions for both the validation process and the routine analysis. 
2.2. Instrumentation 
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For the sample preparation, the following equipment was used: Mettler Toledo PC200 
and AE100 balances (Greifensee, Switzerland), Heidolph Reax 2 overhead mixer 
(Schwabach, Germany), Heraeus Megafuge 1.0 centrifuge (Hanau, Germany), 
Turbovap Zymark Evaporator (Hopkinton, MA, USA) and Whatman Mini-Uniprep 
PVDF 0.45 µm filters (Clifton, NJ, USA). Chromatographic separation and mass 
spectrometry detection was performed with a Xevo TQ MS – Acquity UHPLC system 
coupled to a triple quadrupole tandem mass spectrometer from Waters (Milford, MA, 
USA). The electrospray ion source in positive (ESI+) and negative (ESI-) mode was 
used with data acquisition in multiple reaction monitoring mode (MRM) and analysed 
using Masslynx 4.1 software (Waters). The MRM optimized conditions are presented in 
Table 1. The UHPLC system consisted of a vacuum degasser, an autosampler and a 
binary pump equipped with an analytical reverse-phase column Acquity HSS T3 
2.1x100 mm with 1.8 µm particle size (Waters). The mobile phases used were: [A] 
formic acid 0.1% (v/v) in water and [B] acetonitrile. The gradient program used, at a 
flow rate of 0.45 mL min-1, was: 0-5 min from 97% [A] to 40% [A]; 5-9 min from 40% 
to 0% [A]; 9-10 min from 0% back to 97% [A]; 11-12 min 97% [A].  The column was 
maintained at 40οC, the autosampler at 10οC and the injection volume was 20 µL. 
2.3. Sample preparation 
A portion of 2.0 ± 0.05 g of minced and mixed bovine muscle sample was weighed into 
a 20 mL glass centrifuge tube. The internal standard solution was added, then vortexed 
for 30 ss and allowed to stand in the dark for at least 10 min.  
Afterwards, twelve different extraction procedures were tested; the list of them and the 
main steps are presented in Table 2. 
The liquid extraction was performed by shaking the sample with the solvent using a 
Reax shaker for 20 min followed by centrifugation for 15 min at 3100 g. The 
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supernatant was transferred into a new tube and, for extractions ADry, MDry and EaDry 
evaporated to dryness under a gentle stream of nitrogen, at 40 ºC. For the extract 
samples A, M and Ea the evaporation were just until 0.5 mL. Procedures AHxDry, 
MHxDry, EaHxDry, AHx, MHx and EaHx followed a defat step by adding 3 mL of n-
hexane to the supernatant obtained after centrifugation. The extracts were vortexed for 
30 s s and centrifuged for 15 min at 3100 g. The n-hexane layer were discarded and, for 
extractions AHxDry, MHxDry and EaHxDry evaporated to dryness under a gentle 
stream of nitrogen, at 40 ºC. For extract samples AHx, MHx and EaHx the evaporation 
were just until 0.5 mL. In all procedures, the residue was redissolved with mobile phase 
A (400 µL) or added to the 0.5mL of final extract, filtered through a 0.45 µm PVDF 
Mini-uniprep TM, transferred to vials and injected into the UHPLC-MS/MS under MRM 
optimized conditions for each compound (Table 1). 
2.4. Validation procedure 
The validation procedure followed the described by the EU Commission Decision 
2002/657/EEC (European Commission, 2002). According to those requirements, 
specificity, recovery, repeatability, reproducibility, decision limit (CCα) and detection 
capability (CCβ) were determined.  
The specificity was assessed by analyzing 20 bovine muscle samples from different 
origins to find possible peaks that could interfere with the detection of the analytes of 
interest. The same samples were spiked with all the compounds at the level of interest 
(VL) that, for most of them, corresponds to their MRL/MRPL level, in order to prove 
the identification capability of the method. Calibration curves were assembled with five 
concentration levels: 0.5xVL, 1.0xVL, 1.5xVL, 2.0xVL and 3.0xVL and carried out in 
three different days and with different operators. In each day six replicates of the 
0.5xVL, 1.0xVL and 1.5xVL were executed in order to calculate repeatability, 
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reproducibility and recovery. Recovery determined in the validation process was 
estimated as a ratio between the determined concentration and the real concentration. 
CCα and CCβ were determined according to the following equations (European 
Commission, 2002): 
    2.33 
     (Equation 1, for compounds without MRLs) 
    1.64 
     (Equation 2, for compounds with established MRLs) 
     1.64 
   (Equation 3) 
In which: 
µN is the mean of noise amplitude of twenty blank samples; σN is the standard deviation 
of the noise amplitude of twenty blank samples at the retention time of the target 
antibiotic; σMRL or σVL is the standard deviation at the MRL or VL level in the twenty 
spiked blank samples at that level. For all the determinations, with the exception for the 
studies of absolute recoveries during sample preparation development, the peak areas of 
both the analytes and correspondent internal standard were measured, and the 
analyte/internal standard area ratios were determined. Internal standards were chosen in 
accordance with their similar physic-chemical behaviour with the antibiotics monitored 
and for that they were studied and selected before validation.   
 
3. Results and Discussion 
The principal limitation found while developing multi-detection and multi-class 
methods are related with the sample preparation, mainly due to the difficulty in achieve 
an efficient and generic procedure to extract simultaneously several compounds from 
diverse families with different physic-chemical properties. It is difficult to reach equally 
good recoveries in such methods and minimize the loss of all analytes during sample 
preparation. Multi-step and complex sample clean-up can result in total loss of some 
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target compounds and simplifying the procedure can be an improvement. Therefore and 
considering that the high selectivity of solid-phase-extraction (SPE) can be a problem in 
multi-class methods, a simple liquid extraction was tested and optimized. Twelve 
procedures were experienced and final results, in terms of individual absolute recovery, 
are presented in Table 3. The main purpose of these experiments was to evaluate the 
real impact/recovery that each procedure has in all compounds in order to select the best 
option possible. For that reason, absolute recoveries presented for each method did not 
take into account the presence of the internal standard, in opposition to the recovery 
obtained during validation. 
Three organic solvents were tested for sample extraction: acetonitrile, methanol and 
ethyl acetate. The addition of a quelating agent was also performed, EDTA, especially 
to compete with antibiotics as tetracyclines and macrolides.  It is known that these 
compounds can form complexes with the bi- and trivalent cations present in the sample 
extraction solution which can lead to significant losses of those compounds during the 
procedure. The presence of another compound, as EDTA, which has similar behavior, is 
responsible for the improvement of performance of these antibiotics avoiding drastically 
those losses. 
In some of the experiments a defatting step of the organic layer was introduced, with n-
hexane, to minimize the lipid content from the muscle and thus the potential 
interferences during analysis. Also, because some compounds have better affinity with 
aqueous phase, the same assays were performed without total dryness at the end of the 
extraction (until 0.5 mL).  
Absolute recoveries were calculated for each compound and each methodology in order 
to understand the effects of all variants. The results are presented in Table 3 and, 
graphically compared in Figure 1, by the representation of the minimum and maximum 
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absolute recoveries obtained. In a first analysis of Table 3 and Figure 1 it can be seen 
that worse results were achieved when using ethyl acetate as extracting solvent, 
followed by methanol, being the acetonitrile the organic solvent of choice for the most 
compounds. Comparing the performance of the methods that involved evaporation until 
dryness or until 0.5 mL, it can be easily concluded that the second option gives better 
results. There are two reasons that can justify these data. First of all, the higher affinity 
of polar compounds with aqueous phase can be responsible for a significant amount of 
antibiotics concentrated in the aqueous content of the sample, turned miscible in the 
acetonitrile during homogenization. Also the well-known instability of antibiotics 
(Freitas, Leston, Barbosa, & Ramos, 2013) can be a problem during a longer 
evaporation process of the remaining aqueous layer. Being the acetonitrile the chosen 
organic solvent it remains the comparison between methods A and AHx, with or without 
a defatting step. It can be observed that the recovery is significantly higher when the 
lipid content is reduced from the matrix. The possibility of diminishing the interferences 
coming from the matrix can be responsible for reducing effects like ion suppression or 
enhancement of signal (Kaufmann, 2009; Kinsella, O’Mahony, Cantwell, Furey & 
Danaher, 2009), a common problem in the detection system when working with less 
specific methods such as multi-detection and multi-class and biological samples. 
Nonetheless a compromise had to be adopted selecting the most suitable method, 
although, for some compounds, the recoveries obtained are still significantly low, being 
the worse result the obtained for sulfanilamide with 22%. Briefly, the selected method 
listed with the code AHx above in the sample preparation, in the Table 2 and Figure 1,  
was determinate to be as follow: 2g of homogenized bovine muscle extracted with 
10mL of acetonitrile with 1mL of 0.1M EDTA; after centrifugation the supernatant was 
defatted with n-hexane; centrifuged and evaporated until 0.5 mL of final extract.  
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For recovery correction and to control possible matrix effects, internal standards were 
selected for each group of compounds. The selection was based on their similarities 
with the target compounds, meaning that they should, as much as possible, be equally 
affected by the same fluctuations during extraction procedure, ionization efficiency, 
detection response and chromatographic behavior. Thereby, quantification by matrix 
based calibration curve using internal standards allows to monitor the efficiency of the 
extraction procedure and also to correct possible matrix effects. 
Chromatographic and detection parameters were optimized: mobile phase, flow rate, 
gradient steps and ionization conditions. The conditions described above allow the 
determination of all 41 compounds in less than 10 min, one of the huge advantages of 
UHPLC and for that, chromatographic conditions were tested with the purpose of 
achieve the better efficiency in peak separation and peak shape along with a short run 
time.  
In terms of detection, the ideal MRM conditions were obtained by direct infusion into 
the detector of each standard solution at the concentration of 10µg mL-1. The use of an 
acidified mobile phase, 0.1% of formic acid, promotes the positive ionization, which 
improved the detection of almost all compounds since only chloramphenicol is ionized 
in negative mode. To fulfill the identification criteria demanded in the Decision 
2002/657 (European Commission, 2002), two ion transitions were selected for each 
compound (Table 1). In Figure 2 a representative chromatogram of a spiked bovine 
muscle sample, at the corresponding validation level (VL) is presented. As an example, 
individual MRM of one compound per family of monitored antibiotic is also presented 
in Figure 2. 
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The method was validated in accordance with the European Commission Decision 
2002/657 (European Commission, 2002) that establishes performance criteria for the 
methods and the procedures for their validation.  
The absence of interfering peaks, in the 20 blank bovine muscle analysed samples, 
above a signal-to-noise ratio of 3, was confirmed in all blank samples. Furthermore, 
after spiking the same blank samples, the identification of all compounds was effective 
without any false negative result. The results for precision, in terms of repeatability and 
reproducibility as relative standard deviation (RSD %), recovery, CCα and CCβ are 
summarized in Table 4. Values presented for precision and recovery were calculated for 
the VL that, for most of the compounds are the MRL. To prove the robustness of the 
method, precision is an important parameter that must be analyzed during validation 
since it measures the variability during the analytical process. In terms of repeatability, 
the higher value obtained was for sulfanilamide, with 17%. All the other compounds 
were under that RSD. Regarding reproducibility it was also for sulfanilamide the worse 
value, 22%, while the remaining compounds were below 20%. All these values are in 
accordance with the acceptance criteria, according to the Decision 657/2002 (European 
Commission, 2002). The calculated RSD cannot exceed the level calculated by the 
Horwitz equation that depends on the concentration level. The recovery determined 
during validation was calculated as a ratio between the determined concentration and 
the real concentration. The range values obtained were between 86 and 109% falling 
into the accepted range (European Commission, 2002).  It is important to note that such 
values are different from the ones obtained during the development of sample 
preparation. In these cases the recoveries were calculated as absolute values, without 
having the correction of the internal standard addition, and for that reason values 
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presented in Table 3, for method AHx, are different from the ones calculated during 
validation and described in Table 4.  
CCα and CCβ were calculated according to the equations described above (equation s 1, 
2 and 3) depending if the MRL is established or not. As can be seen in Table 4, 
compounds without tolerance level have lower CCα and CCβ, closer to the limit of 
detection of the method although in the other cases these concentrations are always 
above MRL. 
The results of the validation clearly demonstrated the suitability of this method for the 
detection and identification of all tested antibiotics. 
 
4. Conclusions 
A reliable multi-detection and multi-class method for the determination of 41 antibiotics 
from 7 different classes in bovine muscle was developed. The sample preparation has 
the main advantage of being inexpensive and low time consuming. Also the use of 
UHPLC-MS/MS provided the possibility of analyzing a wide number of samples in 
short period of time. By replacing the methods currently applied in the laboratory (one 
screening method for each class of compounds) the total time from sampling to the final 
result will be reduced in a very significant period of time.  
The method developed was completely validated in order to be used in routine analysis 
of official control for quantitative screening purposes with the possibility of extending 
the method for confirmation. For a laboratory involved in food safety control with a 
large number of antibiotic residues and samples to analyze, the present method is a huge 
improvement. 
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Figure Captions 
 
Figure 1: Minimum and maximum absolute recoveries obtained for the twelve 
extraction procedures for all the antibiotics tested at the concentration of the VL (see 
Table 4 for the respective values). 
 
Figure 2: Chromatogram of individual MRM of one compound per class of antibiotic 
for a spiked bovine muscle sample at the corresponding validation level (VL) 
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Table 1: Multiple reaction monitoring (MRM) acquisition conditions for each antibiotic 
and for the internal standards (IS) used. 
 
 
 
 
 
ESI Precursor ion (m/z) 
Product 
ion (m/z) 
Cone 
voltage 
(V) 
Collision 
energy (eV) 
Retention 
time (min) 
Sulfonamides 
sulfapyridine + 250.3 156.3 30 15 3.27 
sulfadiazine + 251.2 156.2 30 15 3.24 
sulfamethoxazole + 254.4 156.4 30 20 4.26 
sulfathiazole + 256.4 156.3 25 15 3.35 
sulfisoxazole + 268.3 156.2 25 15 4.37 
sulfamethiazole + 271.0 156.2 25 15 3.86 
sulfisomidine + 279.4 186.3 30 16 3.74 
sulfamethazine + 279.4 156.3 30 15 3.77 
sulfamethoxypyridazine + 281.2 156.2 30 15 3.84 
sulfachloropyridazine + 285.3 92.3 30 28 4.15 
sulfadoxine + 311.4 156.4 30 18 4.25 
sulfadimethoxine + 311.4 156.4 30 20 4.65 
sulfanilamide + 173.2 92.1 30 25 1.07 
sulfaquinoxaline + 301.3 92.2 30 30 4.70 
sulfameter (IS) + 281.3 92.2 25 30 3.86 
 
trimethoprim + 291.5 230.3 25 23 3.29 
Tetracyclines 
tetracycline + 445.5 410.3 25 20 3.91 
doxycycline + 445.5 428.2 25 18 3.96 
oxytetracycline + 461.5 426.3 25 20 3.46 
chlorotetracycline + 479.3 444.2 25 20 3.86 
demethyltetracycline (IS) + 465.2 448.3 25 17 3.69 
Macrolides 
erythromycin + 734.5 158.2 25 30 4.22 
spyriamicin + 843.5 174.0 35 35 3.71 
tilmicosin + 869.3 174.2 35 45 3.94 
tylosin + 917.1 174.3 35 35 4.73 
roxithromycin (IS) + 837.7 679.5 30 30 5.43 
Quinolones 
nalidixic acid + 233.2 215.1 40 14 3.81 
flumequine + 262.2 202.1 30 32 5.19 
oxolinic acid + 262.2 216.1 30 25 4.44 
cinoxacin + 263.2 217.1 30 23 4.25 
norfloxacin + 320.3 276.2 20 17 3.45 
enoxacin + 321.2 303.2 35 18 3.40 
ciprofloxacin + 332.2 288.2 35 17 3.48 
danofloxacin + 358.3 96.1 33 21 3.52 
enrofloxacin + 360.3 316.3 31 19 3.58 
ofloxacin + 362.1 261.3 34 26 3.44 
marbofloxacin + 363.3 72.1 30 20 3.36 
lomefloxacin (IS) + 352.2 265.3 31 22 3.54 
Penicillins 
penicillin G + 335.1 176.0 30 25 3.81 
ampicillin + 350.4 106.3 25 20 3.34 
amoxicillin + 366.3 160.3 25 20 4.21 
oxacillin + 402.0 243.0 30 20 5.24 
nafcillin + 415.0 199.0 30 25 5.47 
dicloxacillin + 470.0 311.0 30 25 5.65 
penicillin V (IS) + 351.0 160.2 25 25 5.07 
Amphenicol 
chloramphenicol - 320.9 151.9 30 25 4.25 
chloramphenicol_d5 (IS) - 326.0 157.0 30 25 4.24 
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Table 2: Schematic description of the twelve extraction procedures tested. 
  
Procedure Solvent extraction (10 mL) 
with 1 mL 0.1M EDTA 
Deffating    
(2 mL) Concentration 
ADry acetonitrile 
 
evaporate until 
dryness 
MDry methanol 
EaDry ethyl acetate 
AHxDry acetonitrile 
n-hexane MHxDry methanol 
EaHxDry ethyl acetate 
A acetonitrile 
 
evaporate until 
0.5 mL 
M methanol 
Ea ethyl acetate 
AHx acetonitrile 
n-hexane MHx methanol 
EaHx ethyl acetate 
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Table 3: Absolute recoveries (expressed as %) of the target antibiotics for the twelve 
extractions procedures tested* 
                     Method 
Antibiotics 
ADry  MDry EaDry AHxDry MHxDry EaHxDry A M EA AHx MHx EaHx 
sulfapyridine 88 72 38 76 16 18 99 16 81 99 61 9 
sulfadiazine 46 33 19 38 11 18 95 17 48 104 29 13 
sulfamethoxazole 36 28 2 23 19 16 57 41 6 46 47 14 
sulfathiazole 50 26 5 46 6 8 91 12 18 109 15 6 
sulfisoxazole 36 27 0 13 12 3 53 10 2 45 42 5 
sulfamethiazole 43 25 6 35 6 14 72 19 15 80 20 11 
sulfisomidine 42 38 17 37 21 15 72 18 43 90 54 13 
sulfamethazine 72 62 31 65 41 27 94 37 96 108 96 23 
sulfamethoxypyridazine 28 22 9 24 15 11 60 11 24 64 42 10 
sulfachloropyridazine 66 50 10 50 27 32 83 18 18 102 63 19 
sulfadoxine 54 41 7 46 28 19 80 53 14 104 67 16 
sulfadimethoxine 46 43 12 36 22 14 76 52 31 106 69 17 
sulfanilamide 3 1 3 5 0 10 18 1 3 22 1 9 
sulfaquinoxaline 27 30 5 23 18 8 35 36 14 56 47 9 
trimethoprim 54 36 16 35 15 2 74 19 23 57 47 4 
tetracycline 62 11 17 53 8 23 99 10 36 101 17 19 
doxycycline 57 22 21 53 16 50 92 38 44 106 40 26 
oxytetracycline 35 4 9 26 5 20 54 7 15 72 5 14 
chlorotetracycline 35 9 15 37 8 49 85 11 42 90 15 46 
erythromycin 64 59 9 45 42 5 93 61 17 98 62 16 
spyriamicin 48 50 5 54 35 0 94 58 14 111 77 0 
tilmicosin 27 30 5 25 19 0 69 40 25 81 56 0 
tylosin 49 75 3 40 55 0 74 102 6 98 113 0 
nalidixic acid 81 67 38 72 46 73 92 46 48 105 66 46 
flumequine 46 42 37 42 29 59 75 50 62 107 69 50 
oxolinic acid 62 48 46 56 34 66 87 47 58 106 65 48 
cinoxacin 59 43 21 54 7 76 95 18 34 102 50 60 
norfloxacin 67 45 13 60 27 5 92 40 35 95 56 3 
enoxacin 57 35 14 40 18 6 96 19 33 100 47 6 
ciprofloxacin 60 39 15 52 24 6 67 35 28 100 43 3 
danofloxacin 58 37 14 43 23 0 97 41 30 98 52 1 
enrofloxacin 51 37 16 37 22 8 83 33 36 84 47 13 
ofloxacin 49 27 9 36 18 1 76 31 21 78 39 2 
marbofloxacin 77 53 26 62 29 1 72 23 42 98 67 2 
penicillin G 86 62 12 77 27 0 94 31 34 100 84 0 
ampicillin 50 28 2 21 11 0 87 57 0 65 48 0 
amoxicillin 45 33 22 34 18 0 51 0 0 52 0 0 
oxacillin 39 32 7 39 27 11 101 50 24 101 87 10 
nafcillin 34 23 12 44 17 17 60 36 30 85 40 11 
dicloxacillin 18 22 2 31 16 3 46 31 7 57 33 3 
chloramphenicol 57 77 9 24 30 12 56 6 10 113 9 50 
*Absolute recoveries below 15% are in bold and underlined. 
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Table 4: MRLs and MPRL set by EU for bovine muscle, validation level (VL) and 
validation parameters: decision limit (ccα), detection capability (ccβ), repeatability, 
reproducibility and recovery. 
 
MRL 
*MRPL 
(µg/kg) 
VL 
(µg/kg) 
CCα 
(µg/kg) 
CCβ 
(µg/kg) 
Repeatability 
(%RSD) 
Reproducibility 
(%RSD) 
Recovery 
(%) 
sulfapyridine 100 100 132 164 8 12 109 
sulfadiazine 100 100 113 125 5 8 93 
sulfamethoxazole 100 100 108 117 7 10 108 
sulfathiazole 100 100 107 115 6 8 105 
sulfisoxazole 100 100 111 121 6 9 104 
sulfamethiazole 100 100 110 120 3 5 101 
sulfisomidine 100 100 104 108 3 4 93 
sulfamethazine 100 100 105 110 6 9 100 
sulfamethoxypyridazine 100 100 108 116 2 4 91 
sulfachloropyridazine 100 100 104 108 7 11 103 
sulfadoxine 100 100 110 121 3 5 91 
sulfadimethoxine 100 100 107 114 4 5 93 
sulfanilamide 100 100 105 111 17 22 102 
sulfaquinoxaline 100 100 106 112 5 7 102 
trimethoprim 100 100 108 116 5 7 98 
tetracycline 100 100 125 149 13 20 109 
doxycycline 100 100 123 147 13 20 103 
oxytetracycline 100 100 124 148 13 19 102 
chlorotetracycline 100 100 121 143 12 17 100 
erythromycin 100 100 116 131 9 14 101 
spyriamicin 200 200 226 252 15 20 101 
tilmicosin 50 50 60 71 7 10 93 
tylosin 100 100 116 133 9 14 116 
nalidixic acid - 100 0.01 0.02 8 13 102 
flumequine 200 200 214 229 8 12 104 
oxolinic acid 100 100 114 127 8 12 105 
cinoxacin - 100 0.02 0.04 10 14 108 
norfloxacin - 100 0.02 0.04 9 13 86 
enoxacin - 100 0.04 0.06 10 15 98 
ciprofloxacin - 100 0.09 0.12 9 14 95 
danofloxacin 200 200 229 258 15 20 106 
enrofloxacin 100 100 121 142 12 17 105 
ofloxacin - 100 0.01 0.02 10 15 105 
marbofloxacin - 100 163 176 7 11 100 
penicillin G 50 50 69 87 11 17 94 
ampicillin 50 50 61 73 7 10 97 
amoxicillin 50 50 65 79 8 12 106 
oxacillin 300 300 315 330. 9 13 101 
nafcillin 300 300 307 315 4 6 103 
dicloxacillin 300 300 310 319 6 9 96 
chloramphenicol 0.3* 0.3 0.07 0.10 13 19 105 
 
 
 
